7,681 Shares in Eli Lilly and Company (NYSE:LLY) Bought by Panoramic Capital LLC

Panoramic Capital LLC acquired a new position in Eli Lilly and Company (NYSE:LLY) during the 4th quarter, HoldingsChannel reports. The fund acquired 7,681 shares of the company’s stock, valued at approximately $5,930,000. Eli Lilly and Company accounts for about 3.2% of Panoramic Capital LLC’s investment portfolio, making the stock its 4th largest holding.

A number of other institutional investors have also bought and sold shares of LLY. RMR Wealth Builders boosted its position in Eli Lilly and Company by 2.3% during the fourth quarter. RMR Wealth Builders now owns 4,686 shares of the company’s stock valued at $3,618,000 after acquiring an additional 107 shares during the last quarter. Matrix Trust Co bought a new stake in Eli Lilly and Company during the fourth quarter valued at $164,000. Grassi Investment Management boosted its position in Eli Lilly and Company by 0.3% during the fourth quarter. Grassi Investment Management now owns 79,512 shares of the company’s stock valued at $61,383,000 after acquiring an additional 225 shares during the last quarter. Elmwood Wealth Management Inc. raised its holdings in shares of Eli Lilly and Company by 5.5% during the fourth quarter. Elmwood Wealth Management Inc. now owns 617 shares of the company’s stock valued at $476,000 after purchasing an additional 32 shares during the period. Finally, Sivia Capital Partners LLC raised its holdings in shares of Eli Lilly and Company by 1.8% during the fourth quarter. Sivia Capital Partners LLC now owns 1,844 shares of the company’s stock valued at $1,424,000 after purchasing an additional 32 shares during the period. Institutional investors own 82.53% of the company’s stock.

Insider Buying and Selling

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of the stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $818.24, for a total value of $818,240.00. Following the sale, the chief accounting officer now directly owns 5,840 shares in the company, valued at $4,778,521.60. This represents a 14.62% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.13% of the stock is owned by insiders.

Eli Lilly and Company Stock Down 1.3%

Eli Lilly and Company stock opened at $745.86 on Wednesday. Eli Lilly and Company has a twelve month low of $677.09 and a twelve month high of $972.53. The firm has a 50 day moving average price of $804.15 and a 200-day moving average price of $808.91. The company has a market capitalization of $706.88 billion, a P/E ratio of 63.69, a P/E/G ratio of 1.40 and a beta of 0.48. The company has a quick ratio of 0.97, a current ratio of 1.15 and a debt-to-equity ratio of 2.00.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, May 1st. The company reported $3.34 earnings per share for the quarter, missing analysts’ consensus estimates of $4.64 by ($1.30). The company had revenue of $12.73 billion for the quarter, compared to the consensus estimate of $12.77 billion. Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. The firm’s revenue was up 45.2% on a year-over-year basis. During the same period in the prior year, the company earned $2.58 earnings per share. As a group, equities analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Friday, May 16th will be issued a $1.50 dividend. This represents a $6.00 annualized dividend and a yield of 0.80%. The ex-dividend date of this dividend is Friday, May 16th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 48.82%.

Analyst Ratings Changes

Several brokerages have recently weighed in on LLY. StockNews.com upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Friday, February 7th. Morgan Stanley reiterated an “overweight” rating on shares of Eli Lilly and Company in a report on Thursday, May 1st. Cantor Fitzgerald assumed coverage on shares of Eli Lilly and Company in a report on Tuesday, April 22nd. They issued an “overweight” rating and a $975.00 target price on the stock. Hsbc Global Res lowered shares of Eli Lilly and Company from a “strong-buy” rating to a “moderate sell” rating in a report on Monday, April 28th. Finally, Guggenheim restated a “buy” rating on shares of Eli Lilly and Company in a report on Thursday, May 1st. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and nineteen have issued a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $1,002.80.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.